TScan Q4 net loss $19.6M; all 8 TSC-100/101 patients relapse-free

TScan Therapeutics, Inc.

Q4 revenue $7.2M (up from $3.1M YoY); full-year revenue $21.0M. R&D expenses $22.4M Q4, $88.2M full year.
Cash $192M as of Dec 31, 2023; cash runway into 2026.
Phase 1 heme data: 8/8 treatment-arm patients relapse-free; one high-risk MDS patient reached 1 year post-TSC-101.
FDA cleared INDs for TSC-201-B0702 (MAGE-C2) and TSC-204-A0101 (MAGE-A1); solid tumor trial enrolling.
Appointed Jason Amello as CFO, Justin McCue as CTO; promoted several executives.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TScan Therapeutics, Inc. reported financial results for the three months and full year ended December 31, 2023.

Period: the three months and full year ended December 31, 2023
Result: reported results

Exact text from the filing

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2023, and provided a business update.

View on SEC.gov

1048 earnings releases filed in the last 30 days. Browse all earnings releases →

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-026868

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.